ADA 2026
American Diabetes Association · Scientific Sessions
本頁以 議程（Agenda）視圖呈現：依 session 分組，每個 session 下列出各場 talk 的講者、主題與重點預覽。只收錄具有 on-demand 錄影回播的場次，附逐字稿、投影片與摘要。
註：與導覽列「2026 ADA」（學會年度治療指引）為不同頁面——此處專注於 ADA 2026 大會現場演講。
27 sessions · 119 talks
Fri · 5 Jun
23 sessions歡迎來到 2026 ADA 科學年會：Richard Woychik, PhD 主題演講與 Pathway to Stop Diabetes 研討會｜Welcome to the 2026 ADA Scientific Sessions: Keynote Address by Richard Woychik, PhD & 'Pathway to Stop Diabetes' Symposium
- 1/8
歡迎來到 2026 ADA 科學年會
Welcome to the 2026 ADA Scientific Sessions!
Prevention開幕致詞：從胰島素到 β 細胞替代，迎向全球糖尿病與肥胖大流行的挑戰
- 2/8
開場引言
Welcome to the 2026 ADA Scientific Sessions: Keynote Address by Richard Woychik, PhD & 'Pathway to Stop Diabetes' Symposium - Introduction
PreventionADA 倡議：擴大研究經費、將胰島素月費上限納入全民保險
- 3/8
主題演講：糖尿病的未來——NIH 的下世代研究願景
Keynote Address: The Future of Diabetes—NIH’s Vision for Transforming Diabetes Research in the Next Generation
PreventionNIH 以全人健康視角整合多平台，系統性探究糖尿病的根本成因並轉化至基層
- 4/8
爐邊對談：NIH 的糖尿病研究方向
Welcome to the 2026 ADA Scientific Sessions: Keynote Address by Richard Woychik, PhD & 'Pathway to Stop Diabetes' Symposium - Fireside Chat
Prevention以「黃金標準科學」探究病因，並平衡專家評審與戰略導向的科研資助
- 5/8
「Pathway to Stop Diabetes」研討會引言
Introduction to 'Pathway to Stop Diabetes' Symposium
Prevention支持青年研究員、營造高風險高回報環境，推動研究從基礎走向臨床
- 6/8
能在發病前阻止糖尿病嗎？橫跨生命歷程的精準預防
Can we Stop Diabetes Before it Begins? Precision Prevention across the Life Course
Prevention以胚胎源性疾病觀與精準醫學，在生命早期阻斷糖尿病跨世代傳遞
- 7/8
進食時機很重要：晝夜節律失調如何驅動代謝疾病
When We Eat Matters: How Disrupted Circadian Rhythms Drive Metabolic Disease
Prevention進食時間失調擾亂脂肪組織生物鐘；早期限時飲食可改善代謝健康
- 8/8
運用蛋白體學與 AI 優化飲食以預防糖尿病
Optimizing Diet for Global Diabetes Prevention Leveraging Proteomics and AI
Prevention結合蛋白體學與 AI，打造因地制宜的個人化飲食以預防第 2 型糖尿病
Building a Multidisciplinary Model for Behavior Change in Cardiometabolic Health - Panel Discussion
中斷久坐與運動休息｜Exercise Breaks
- 1/3
Metabolic Effects of Active Breaks to Sitting vs. Continuous Walking in Adults with Prediabetes: Preliminary Results from the BURST2D Study
Exercise Breaks - 2/3
Heart-Rate Monitoring for Early Detection of Physical Activity–Induced Hypoglycemia in Type 1 Diabetes
Exercise Breaks - 3/3
Wearables-Derived Physical Activity Is Independently Associated with Lower Odds of Type 2 Diabetes in the All of Us Research Program
Exercise Breaks
人人可用的連續酮體監測（CKM）：風險還是值得？｜Continuous Ketone Monitoring for the Masses: Risky or Rewarding?
- 1/5
Continuous Ketone Monitoring for the Masses: Risky or Rewarding? - Pro (Jennifer L Sherr)
Innovation - 2/5
Continuous Ketone Monitoring for the Masses: Risky or Rewarding? - Con (Jeremy Pettus)
Innovation - 3/5
Continuous Ketone Monitoring for the Masses: Risky or Rewarding? - Rebuttal (Jennifer L Sherr)
Innovation - 4/5
Continuous Ketone Monitoring for the Masses: Risky or Rewarding? - Rebuttal (Jeremy Pettus)
Innovation - 5/5
Continuous Ketone Monitoring for the Masses: Risky or Rewarding? - Question and Discussion Period
Innovation
人類胰島細胞身分與組織結構｜Human Islet Cell Identity and Organization
- 1/4
Senotype Blueprint of the Human Endocrine Pancreas
Human Islet Cell Identity and Organization - 2/4
Modeling In Utero Glucose Exposure Using Indigenous American HiPSC-Derived Pancreatic Islets
Human Islet Cell Identity and Organization - 3/4
Spatial Organization of Human Islet Endocrine Cells Modulates Stimulated Hormone Secretion
Human Islet Cell Identity and Organization - 4/4
Identifying Diabetes-Relevant Gene Programs across Metabolic Tissues in the Common Metabolic Diseases Knowledge Portal
Human Islet Cell Identity and Organization
希望還是炒作？微生物體作為第 2 型糖尿病與肥胖的新前沿｜Hope or Hype? Microbiome as New Frontier for Type 2 Diabetes and Obesity
- 1/5
Microbiome on the Menu: Yes, It Has a Role to Play in Cardiometabolic Health
Hope or Hype? Microbiome as New Frontier for Type 2 Diabetes and Obesity - 2/5
Targeted Microbiome Modification: Not Quite Ready for Clinical Practice
Hope or Hype? Microbiome as New Frontier for Type 2 Diabetes and Obesity - 3/5
Hope or Hype? Microbiome as New Frontier for Type 2 Diabetes and Obesity - Rebuttal (Henrik Munch Roager)
Hope or Hype? Microbiome as New Frontier for Type 2 Diabetes and Obesity - 4/5
Hope or Hype? Microbiome as New Frontier for Type 2 Diabetes and Obesity - Rebuttal (Karen Corbin)
Hope or Hype? Microbiome as New Frontier for Type 2 Diabetes and Obesity - 5/5
Hope or Hype? Microbiome as New Frontier for Type 2 Diabetes and Obesity - Question and Discussion Period
Hope or Hype? Microbiome as New Frontier for Type 2 Diabetes and Obesity
第 1 型糖尿病的免疫異質性與內型：來自人體研究與人源化模型的洞見｜Immune Heterogeneity and Endotypes in Type 1 Diabetes: Insights from Human Studies and Humanized Models
糖尿病視網膜病變管理：臨床觀點｜Management of Diabetic Retinopathy—Clinical Perspective
- 1/4
CGM-Derived Metrics Outperform Hemoglobin A1c in Predicting Microvascular Complications in Type 1 Diabetes: Multicenter Data from Saudi Arabia
Management of Diabetic Retinopathy—Clinical Perspective - 2/4
The SURPASS-CVOT Retinopathy Substudy: Retinal Status after Treatment with Tirzepatide or Dulaglutide in Patients with Type 2 Diabetes and Risk for Progressive Retinopathy
Management of Diabetic Retinopathy—Clinical Perspective - 3/4
Differential Association of Clinical and Biochemical Factors in Diabetic Retinopathy and Age-Related Macular Degeneration in Type 1 and 2 Diabetes
Management of Diabetic Retinopathy—Clinical Perspective - 4/4
Genetic Modifiers of Phenotypic Divergence in Diabetic Retinopathy
Management of Diabetic Retinopathy—Clinical Perspective
肥胖治療的人體研究：新興治療選項與決策策略｜Human Studies in Obesity Treatment: Emerging Therapeutic Options and Strategies for Decision-Making
- 1/3
Early Weight Loss Velocity Guides Precision Escalation in Obesity Treatment
Obesity - 2/3
Efficacy and Safety of Dual GLP-1/GIP Receptor Agonist HDM1005 in Obese Participants without Diabetes: A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Trial
Obesity - 3/3
Effects of CagriSema on Appetite and Functional Brain Activity in People with Overweight/Obesity
Obesity
胰島素阻抗：代謝功能障礙的原因還是結果？｜Insulin Resistance: A Cause or Consequence of Metabolic Dysfunction?
- 1/4
Ceramides and the Lipotoxic Basis of Insulin Resistance
Cardiometabolic - 2/4
Adipose Insulin Resistance as a Driver of Metabolic Dysfunction
Cardiometabolic - 3/4
A Genetic Perspective with Evidence for the Existence of Both
Cardiometabolic - 4/4
Insulin Resistance: A Cause or Consequence of Metabolic Dysfunction? - Question and Discussion Period
Cardiometabolic
超越 A1C：早期第 1 型糖尿病疾病進展的新評估方式？（含 ADA 主席精選摘要）｜Beyond A1C: New Ways to Measure Disease Progression in Early-Stage Type 1 Diabetes? (With ADA Presidents’ Select Abstract Presentation)
- 1/4
ADA Presidents' Select Abstract: Time to Minimal Residual C-Peptide as an Efficacy Measure in Recent-Onset Type 1 Diabetes Immunotherapy Trials
Beta cell - 2/4
Extracellular Vesicle (EV) Proteomics Distinguishes Partial Clinical Remission (PCR) in New-Onset Type 1 Diabetes (T1D)
Beta cell - 3/4
Increase in Insulin Clearance Features Rapid Disease Progression in Children with Preclinical Type 1 Diabetes (T1D)
Beta cell - 4/4
Divergent Exocrine Pancreatic Trajectories in Children Progressing to Stage 1 vs. Stage 3 Type 1 Diabetes
Beta cell
超越傳統照護：糖尿病足潰瘍的再生醫學與智慧敷料｜Beyond Conventional Care: Regenerative Medicine and Smart Dressings for Diabetic Foot Ulcer
- 1/3
Endothelial Metallothionein Enables VEGF Therapy in Diabetic Ischemic Wound Healing
Complications - 2/3
Effectiveness of Topical Insulin vs. Saline Dressings for Diabetic Foot Ulcer Management: A Systematic Review and Meta-Analysis
Complications - 3/3
Bedside Blind Bone Biopsy (B4) for Suspected Diabetic Foot Osteitis: A 10-Year Practice in a French Diabetes Unit
Complications
重新設計糖尿病照護：成本是多少？｜Redesigning Diabetes Care: What Is the Cost?
- 1/4
Continuous Glucose Monitoring (CGM) Coverage Policy, Access, and Utilization in Nonprofit Community Health Plans
Innovation - 2/4
Cost-Effectiveness of Bariatric Surgery for Preventing Diabetes in U.S. Adults with Prediabetes and Severe Obesity: A Simulation Study
Innovation - 3/4
Cost-Effectiveness of Age-Specific Remote Education to Initiate and Sustain Use of CGM in Older Adults with Diabetes on Insulin
Innovation - 4/4
Patient and Cost Outcomes of a Proactive Certified Diabetes Care and Education Specialists (CDCES) Program
Innovation
重點研究摘要：糖尿病腎病變機轉｜Top Research Abstracts: Mechanisms of Diabetic Kidney Disease
- 1/3
Targeted Deletion of Sphingosine 1-Phosphate Receptor 1 (S1PR1) in T Cells Confers Renoprotection in Diabetic Mice
Complications - 2/3
Expanding the Target Space for DKD: A Multiplexed Characterization of AAV Cellular Tropism Targeting Tubular Epithelial Cells for High Throughput In Vivo Perturb-seq
Complications - 3/3
The CEBPβ-XOR Axis and Genetic Risk for Metabolic Dysfunction–Associated Kidney Disease
Complications
什麼有效？第 1 型、第 2 型與妊娠糖尿病行為介入試驗成果｜What Works? Outcomes of Behavioral Intervention Trials in Type 1, Type 2, and Gestational Diabetes
- 1/5
Differences in Glycemic and Psychosocial Gains: Effects of the HAPPY-T1D Intervention
What Works? Outcomes of Behavioral Intervention Trials in Type 1, Type 2, and Gestational Diabetes - 2/5
The T1D-CATCH Study: Community Health Workers (CHWs) Increase Diabetes Technology Uptake in Young Adults (YA) with Type 1 Diabetes (T1D)
What Works? Outcomes of Behavioral Intervention Trials in Type 1, Type 2, and Gestational Diabetes - 3/5
Mitraa-T1D: A Multicenter Randomized Trial of a Digital Conversational Support Tool in Adults with Type 1 Diabetes
What Works? Outcomes of Behavioral Intervention Trials in Type 1, Type 2, and Gestational Diabetes - 4/5
Effects of a Camp-Style Lifestyle Modification Program on Diabetes Prevention in Rural Women with Prior GDM
What Works? Outcomes of Behavioral Intervention Trials in Type 1, Type 2, and Gestational Diabetes - 5/5
Integrating Behavioral, Medical, and E-health Care to Improve Glycemic Management among Latino Adults: Results from the LUNA-E Randomized Clinical Trial
What Works? Outcomes of Behavioral Intervention Trials in Type 1, Type 2, and Gestational Diabetes
低血糖的不同情境：風險、辨識與真實世界安全性（含 ADA 主席精選摘要）｜Hypoglycemia across Contexts: Risk, Recognition, and Real-World Safety (With ADA Presidents' Select Abstract Presentation)
- 1/6
ADA Presidents' Select Abstract: Food Insecurity and Level 3 Hypoglycemia in Non-Insulin-Treated Secretagogue Users (iNPHORM, USA)
Complications - 2/6
Neighborhood Affluence and Disadvantage Are Associated with Level 3 Hypoglycemia (Lv3 Hypo) in Adults with Type 1 Diabetes (T1D) Regardless of Diabetes Technology Use
Complications - 3/6
Poor Correlation between Hypoglycemic Symptoms and Heart Rate Response in Sensor-Detected Hypoglycemia in T2D: Hypo-METRICS Study
Complications - 4/6
Normalization of Asymptomatic Hypoglycemia Is Associated with Reduced Self-Care Behaviors in Adults with Type 1 Diabetes
Complications - 5/6
Hybrid Closed-Loop Increases Time in Tight Range while Reducing Hypoglycemia in Older Adults with Type 1 Diabetes: Pooled Analysis from Three Randomized Controlled Trials
Complications - 6/6
Driving and Diabetes: Differences in Driving Behaviours between U.S. and UK Drivers with Insulin-Treated Type 2 Diabetes
Complications
從餐盤到胰臟：飲食連結糖尿病的機制（含 ADA 主席精選摘要）｜From Plate to Pancreas: Mechanisms Linking Diet to Diabetes (With ADA Presidents' Select Abstract Presentation)
- 1/6
ADA Presidents' Select Abstract: One-Year Metabolic Improvements in Midlife Women in a Digital Nutritional Program
Complications - 2/6
Coffee Intake Timing, Metabolomics, and Diabetes: A Prospective Study in the Hispanic Community Health Study/Study of Latinos (HCHSL/SOL)
Complications - 3/6
VeggieRx: A Produce Prescription Program to Improve Glycemic, Blood Pressure, and Weight Outcomes in Adults with Diabetes and Prediabetes in South Carolina
Complications - 4/6
Neighborhood Food Environments and Incidence of Type 2 Diabetes after Gestational Diabetes: A Population-Based Cohort Study in New York City
Complications - 5/6
FTO Genotype Modifies the Association between Dietary Fiber Intake and Obesity in Type 2 Diabetes: The Fukuoka Diabetes Registry
Complications - 6/6
Associations and Interactions of Genetic Predispositions for Taste Preferences and Socioeconomic Status with Hyperpalatable Food Intake
Complications
為所有人調整糖尿病照護（含 Felicia Hill-Briggs 健康公平先驅獎講座）｜Adapting Diabetes Care for All (With Felicia Hill-Briggs Trailblazer in Health Equity Award Lecture)
- 1/5
Felicia Hill-Briggs Trailblazer in Health Equity Award Lecture
Adapting Diabetes Care for All (With Felicia Hill-Briggs Trailblazer in Health Equity Award Lecture) - 2/5
Culturally Tailored Collaborative Care: Sustained Cardiometabolic Outcomes and Cost Savings for High-Risk Asian American Adults
Adapting Diabetes Care for All (With Felicia Hill-Briggs Trailblazer in Health Equity Award Lecture) - 3/5
Hemoglobin A1c Reduction after Participation in Blue Circle Health's Novel Type 1 Diabetes Care Program
Adapting Diabetes Care for All (With Felicia Hill-Briggs Trailblazer in Health Equity Award Lecture) - 4/5
Improving Diabetes Eye Disease Screening Rates in Under-Resourced Communities
Adapting Diabetes Care for All (With Felicia Hill-Briggs Trailblazer in Health Equity Award Lecture) - 5/5
How Organizations Sustain the National Diabetes Prevention Program: A Qualitative Study
Adapting Diabetes Care for All (With Felicia Hill-Briggs Trailblazer in Health Equity Award Lecture)
理解心血管風險的新舊工具（含 Edwin Bierman Award Lecture）｜Old and New Tools to Understand Cardiovascular Risk (With Edwin Bierman Award Lecture)
- 1/4
Edwin Bierman Award Lecture: Low Cardiopulmonary Fitness in Diabetes; An Understudied Microvascular
Old and New Tools to Understand Cardiovascular Risk (With Edwin Bierman Award Lecture) - 2/4
Integrated Metabolomic, Proteomic, and Genomic Biomarkers Improve Identification of Coronary Artery Disease in East Asians with Type 2 Diabetes
Old and New Tools to Understand Cardiovascular Risk (With Edwin Bierman Award Lecture) - 3/4
Uncovering Sex Differences in Macro- and Microvascular Complications in Type 2 Diabetes
Old and New Tools to Understand Cardiovascular Risk (With Edwin Bierman Award Lecture) - 4/4
Rates of Cardiovascular Disease and Heart Failure among Diabetes Subtypes Relative to Adults without Diabetes
Old and New Tools to Understand Cardiovascular Risk (With Edwin Bierman Award Lecture)
第 1 場：胰島素輸注系統的新進展（含 ADA 主席精選摘要）｜Session #1: What's New with Insulin Delivery Systems? (With ADA Presidents' Select Abstract Presentation)
- 1/6
ADA Presidents' Select Abstract: Automated Insulin Delivery in Hospitalized Patients with Diabetes and Advanced Kidney Disease
Complications - 2/6
Independent Impact of Physical Activity Characteristics and Initial Metabolic State on Glycemic Outcomes in the DBLG1 System: A Linear Mixed-Model Analysis
Complications - 3/6
Negative Premeal NetIOB and Large Meals Are Associated with Higher Postprandial Excursions in AID Users with Type 1 Diabetes
Complications - 4/6
Menstrual Cycle–Related Insulin Requirement Changes Are Independent of Menstrual Symptoms and PMDD in Women with Type 1 Diabetes Using an AHCL System
Complications - 5/6
A Multicenter Trial Assessing the Efficacy and Safety of the Novel Twiist Automated Insulin Delivery (AID) System in Adults with Insulin-Treated Type 2 Diabetes (T2D)
Complications - 6/6
Multicenter, Randomized Trial of a Next-Generation Algorithm for Omnipod in Individuals with Type 1 or Type 2 Diabetes: The STRIVE Trial
Complications
賦能族群照護：糖尿病自我管理教育的實務應用｜Empowering Populations: Diabetes Self-Management Education in Practice
- 1/4
Diabetes Self-Management Education (DSME) and Hospital Admission Rates in Adults with Type 2 Diabetes in England: An Epidemiological Analysis
Complications - 2/4
Enhancing A “Food Is Medicine Program” with Coaching from Community Health Workers Shows Significant Improvements in Health Outcomes for People with Diabetes
Complications - 3/4
Deafdiabetescan.org: A Diabetes Digital Health Education Website in American Sign Language
Complications - 4/4
Evaluating Feasibility of Type 1 Diabetes Education and Support (T1DES) Intervention to Improve Diabetes Distress among Black Young Adults
Complications
預防第 1 型糖尿病｜Preventing Type 1 Diabetes
- 1/6
Fcµ Fragment of IgM: A Novel Tolerance-Restoring Therapeutic for Autoimmune Type 1 Diabetes
Preventing Type 1 Diabetes - 2/6
Operationalizing Early-Stage Type 1 Diabetes Screening and Monitoring: A Pediatric Multicenter T1D Exchange Quality Improvement Initiative
Preventing Type 1 Diabetes - 3/6
TEPLI-REAL: A Real-World Retrospective Study Characterizing Individuals with Type 1 Diabetes Treated with Teplizumab and Their Metabolic Outcomes
Preventing Type 1 Diabetes - 4/6
Clinical Safety, Pharmacokinetics, Immunogenicity, and Pharmacodynamics following Repeat Dosing of SAB-142, a Fully Human Multispecific Antithymocyte Globulin for New-Onset Type 1 Diabetes
Preventing Type 1 Diabetes - 5/6
N-104, Next-Gen Dual-Action Immunoregulatory and Regenerative Therapy for Type 1 Diabetes
Preventing Type 1 Diabetes - 6/6
Residual β-Cell Function Confers Glycemic Benefit beyond Automated Insulin Delivery in New-Onset Type 1 Diabetes
Preventing Type 1 Diabetes
妊娠期血糖異常對新生兒與兒童的影響（含 Norbert Freinkel Award Lecture）｜Neonatal and Childhood Outcomes of Dysglycemia in Pregnancy (With Norbert Freinkel Award Lecture)
- 1/4
Associations of Early Pregnancy Maternal Glycemic and Metabolic Measures with Newborn Adiposity
Neonatal and Childhood Outcomes of Dysglycemia in Pregnancy (With Norbert Freinkel Award Lecture) - 2/4
Norbert Freinkel Award Lecture: Understanding Diabetic Embryopathy—Roles of Oxidative Stress and Embryo Gene Expression
Neonatal and Childhood Outcomes of Dysglycemia in Pregnancy (With Norbert Freinkel Award Lecture) - 3/4
Early-Life Hypoglycemia, Developmental Disorders, Neurodiversity, and Psychiatric Disease: A Real-World Observational Study
Neonatal and Childhood Outcomes of Dysglycemia in Pregnancy (With Norbert Freinkel Award Lecture) - 4/4
Gestational Diabetes Mellitus (GDM), Cord Blood Metabolomics, and Random Plasma Insulin Levels in Childhood
Neonatal and Childhood Outcomes of Dysglycemia in Pregnancy (With Norbert Freinkel Award Lecture)
Sat · 6 Jun
2 sessionsADA 糖尿病照護標準 2026 更新｜The ADA's Standards of Care in Diabetes: 2026 Updates
- 1/6
Facilitating Positive Health Behaviors and Well-Being to Improve Health Outcomes
Complications - 2/6
Pharmacological Approaches to Glycemic Management
Complications - 3/6
Diabetes Technology
Complications - 4/6
Cardiovascular Disease and Risk Management
Complications - 5/6
Management of Diabetes in Pregnancy
Complications - 6/6
Diabetes in Children and Adolescents
Complications
How to Best Combine Therapies for Patients with Diabetic Kidney Disease?
- 1/5
Sequential Addition
How to Best Combine Therapies for Patients with Diabetic Kidney Disease? - 2/5
Simultaneous Initiation
How to Best Combine Therapies for Patients with Diabetic Kidney Disease? - 3/5
How to Best Combine Therapies for Patients with Diabetic Kidney Disease? - Rebuttal (Ian de Boer)
How to Best Combine Therapies for Patients with Diabetic Kidney Disease? - 4/5
How to Best Combine Therapies for Patients with Diabetic Kidney Disease? - Rebuttal (Amy Mottl)
How to Best Combine Therapies for Patients with Diabetic Kidney Disease? - 5/5
How to Best Combine Therapies for Patients with Diabetic Kidney Disease? - Question and Discussion Period
How to Best Combine Therapies for Patients with Diabetic Kidney Disease?
Sun · 7 Jun
2 sessions共同目標：血壓、血脂與心衰竭治療指引最新更新｜Goals in Common: Recent Updates to the Guidelines—Blood Pressure, Lipids, and Heart Failure
- 1/4
How Low to Go? And in Whom? New Blood Pressure Targets in Diabetes
Cardiometabolic - 2/4
Lipid Guidelines and Goals: Focus on Diabetes
Cardiometabolic - 3/4
Preventing Heart Failure in Diabetes
Cardiometabolic - 4/4
Goals in Common: Recent Updates to the Guidelines—Blood Pressure, Lipids, and Heart Failure - Question and Discussion Period
Cardiometabolic
GLP-1 受體促效劑減重中的肌肉流失：真實疑慮還是過度擔心？｜Muscle Loss in GLP-1 Receptor Agonist-Induced Weight Loss: A Real Concern or Much Ado about Nothing?
- 1/5
Muscle Loss Is Adaptive
Complications - 2/5
Muscle Loss Is Maladaptive
Complications - 3/5
Muscle Loss in GLP-1 Receptor Agonist–Induced Weight Loss: A Real Concern or Much Ado about Nothing? - Rebuttal (Sam Klein)
Complications - 4/5
Muscle Loss in GLP-1 Receptor Agonist–Induced Weight Loss: A Real Concern or Much Ado about Nothing? - Rebuttal (Eric Ravussin)
Complications - 5/5
Muscle Loss in GLP-1 Receptor Agonist–Induced Weight Loss: A Real Concern or Much Ado about Nothing? - Question and Discussion Period
Complications